IBD: Crohn's Disease

Biosimilar Library

All of our biosimilars content in one place to help Inflammatory Bowel Disease (IBD) patients best understand the process of switching from a reference biologic to a biosimilar.

Everything you need to know about biosimilars in Canada

Both biologics and biosimilars have gone through rigorous standards for authorization by Health Canada, to which both have been found safe and effective for use in Inflammatory Bowel Disease (IBD).  

CDHF knows having to change any kind of medication can be very stressful.  CDHF’s Biosimilar library has many informative resources to help make your transition to your new medication seamless.

Explore Now:


What is a Biosimilar?

A biosimilar is a drug proven to be highly similar to a biologic drug that has been authorized for sale in Canada (known as the reference biologic drug). Biosimilars have been approved by Health Canada based on a thorough comparison to a reference biologic drug and may enter the market after the reference biologic drugs’ patents and data protection has expired. Biosimilar products first entered the Canadian market in 2009. Health Canada has already approved over 30 biosimilars, including some that are used to treat IBD (Crohn’s disease and ulcerative colitis): Inflectra (infliximab), Renflexis (infliximab), Avsola (infliximab), Hadlima (adalimumab), Idacio (adalimumab), Hyrimoz (adalimumab), Amgetiva (adalimumab) and Hulio (adalimumab).

Quality and Safety Around Biosimilars

To be approved in Canada, a biosimilar must be proven to have no clinically meaningful differences to the reference biologic. This means, studies of the biosimilar MUST show that there are no differences in outcomes for patients taking a biosimilar, compared to those taking a reference biologic drug. Rigorous standards for authorization by Health Canada mean that patients and health care providers can have the same confidence in the quality, safety and efficacy of a biosimilar.

Transitioning to a Biosimilar is Safe and Effective

Health Canada supports switching from a biologic to a biosimilar and considers that a one-time switch from a reference biologic drug to a biosimilar to be acceptable. Health Canada also recommends that the decision to switch be made by the physician/prescriber and patient, taking into account any policies of the relevant jurisdiction.

Transition Pathway Brochure: Get the Basic Facts

IBD: Switching from a Biologic to a Biosimilar

NEW! CDHF Talks: Your New Infusion Clinic ‘Not the Same but Very Similar’

What’s Health Canada Saying About Biosimilars? Video

What’s Health Canada Saying About Biosimilars? Infographic

Effie’s Experience with Switching to a Biosimilar

Have you been switched/transitioned to a biosimilar version of Remicade® (infliximab)?

CDHF wants to understand the recent experiences of people living in Canada who have switched/transitioned from Remicade® (infliximab) to the biosimilar versions of infliximab: Inflectra® and Renflexis™.
If you haven’t been asked to switch/transition yet, please note that we will keep this survey open for a few months so you can come back to it and complete it. 

This survey is only for people living in the Canada, aged 18+ who have switched/transitioned from the biologic Remicade® to the biosimilar Inflectra® or Renflexis™.


Other Relevant Resources:

Biosimilar Library

All of our biosimilars content in one place to help Inflammatory Bowel Disease (IBD) patients best understand the process of switching from a reference biologic to a biosimilar.

Everything you need to know about biosimilars in Canada

Both biologics and biosimilars have gone through rigorous standards for authorization by Health Canada, to which both have been found safe and effective for use in Inflammatory Bowel Disease (IBD).  

CDHF knows having to change any kind of medication can be very stressful.  CDHF's Biosimilar library has many informative resources to help make your transition to your new medication seamless.

Explore Now:


What is a Biosimilar?

A biosimilar is a drug proven to be highly similar to a biologic drug that has been authorized for sale in Canada (known as the reference biologic drug). Biosimilars have been approved by Health Canada based on a thorough comparison to a reference biologic drug and may enter the market after the reference biologic drugs’ patents and data protection has expired. Biosimilar products first entered the Canadian market in 2009. Health Canada has already approved over 30 biosimilars, including some that are used to treat IBD (Crohn’s disease and ulcerative colitis): Inflectra (infliximab), Renflexis (infliximab), Avsola (infliximab), Hadlima (adalimumab), Idacio (adalimumab), Hyrimoz (adalimumab), Amgetiva (adalimumab) and Hulio (adalimumab).

Quality and Safety Around Biosimilars

To be approved in Canada, a biosimilar must be proven to have no clinically meaningful differences to the reference biologic. This means, studies of the biosimilar MUST show that there are no differences in outcomes for patients taking a biosimilar, compared to those taking a reference biologic drug. Rigorous standards for authorization by Health Canada mean that patients and health care providers can have the same confidence in the quality, safety and efficacy of a biosimilar.

Transitioning to a Biosimilar is Safe and Effective

Health Canada supports switching from a biologic to a biosimilar and considers that a one-time switch from a reference biologic drug to a biosimilar to be acceptable. Health Canada also recommends that the decision to switch be made by the physician/prescriber and patient, taking into account any policies of the relevant jurisdiction.

Transition Pathway Brochure: Get the Basic Facts

[flipbook pdf="https://cdhf.ca/wp-content/uploads/2021/04/CDHF-EnglishBiosimilarTransitionPathwayBrochure.pdf"]

IBD: Switching from a Biologic to a Biosimilar

https://www.youtube.com/watch?v=FGnumLGw-A0

NEW! CDHF Talks: Your New Infusion Clinic 'Not the Same but Very Similar'

https://www.youtube.com/watch?v=9elGP7dyPe4

What’s Health Canada Saying About Biosimilars? Video

https://www.youtube.com/watch?v=6DkzQFdyNuY

What’s Health Canada Saying About Biosimilars? Infographic

Effie's Experience with Switching to a Biosimilar

https://www.youtube.com/watch?v=E7Gr4HJ54FY

Have you been switched/transitioned to a biosimilar version of Remicade® (infliximab)?

CDHF wants to understand the recent experiences of people living in Canada who have switched/transitioned from Remicade® (infliximab) to the biosimilar versions of infliximab: Inflectra® and Renflexis™.
If you haven't been asked to switch/transition yet, please note that we will keep this survey open for a few months so you can come back to it and complete it. 

This survey is only for people living in the Canada, aged 18+ who have switched/transitioned from the biologic Remicade® to the biosimilar Inflectra® or Renflexis™.


Other Relevant Resources: